| Literature DB >> 27074843 |
Abstract
There are increasing numbers of breast cancer survivors. Chemotherapy or endocrine therapy result in effects on vaginal health that may affect quality of life. These effects may impact sexual function, daily comfort, or the ability to perform a pelvic examination. Vulvovaginal atrophy, or genitourinary syndrome of menopause, may be treated with nonhormonal or hormonal measures. Breast cancer survivors who are menopausal and/or on endocrine therapy should be screened for issues with vaginal health and counseled about treatment options.Entities:
Keywords: Breast cancer; Conjugated equine estrogens; Dyspareunia; Genitourinary syndrome of menopause; Menopause; Premature ovarian failure; Vaginal dryness; Vaginal estrogen therapy; Vaginal lubricants; Vulvovaginal atrophy
Mesh:
Substances:
Year: 2016 PMID: 27074843 DOI: 10.1007/s11912-016-0517-x
Source DB: PubMed Journal: Curr Oncol Rep ISSN: 1523-3790 Impact factor: 5.075